Title : Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.

Pub. Date : 2012 Apr 15

PMID : 22133480






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate interferon beta 1 Homo sapiens
2 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate interferon beta 1 Homo sapiens
3 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate interferon beta 1 Homo sapiens
4 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate interferon beta 1 Homo sapiens